Apogee Therapeutics, Inc. APGE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s EPS (diluted)?
- Apogee Therapeutics, Inc. (APGE) reported EPS (diluted) of -$1.06 in Q1 2026.
- How has Apogee Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Apogee Therapeutics, Inc.'s EPS (diluted) decreased by 11.6% year-over-year, from -$0.95 to -$1.06.
- What is the long-term trend for Apogee Therapeutics, Inc.'s EPS (diluted)?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s EPS (diluted) has grown at a -23.0% compound annual growth rate (CAGR), from -$7.12 to -$4.22.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.